Project Oncology‪®‬ ReachMD

Host: Jennifer Caudle, DO

Guest: Joyce O'Shaughnessy, MD



The results from the phase III EMERALD trial led to the approval of ORSERDU® (elacestrant) as the first oral selective estrogen receptor degrader for ER-positive/HER2-negative metastatic breast cancer patients with ESR1 mutations after disease progression following at least one line of endocrine therapy.1 But given the results from prior analyses, clinicians wanted to better understand the data for elacestrant in subgroups of patients with key clinical or biomarker characteristics, and so a post hoc analysis of elacestrant in these subgroups who typically have a poorer prognosis was conducted. Explore the EMERALD trial and the key outcomes from this subgroup analysis with Dr. Jennifer Caudle and medical oncologist Dr. Joyce O'Shaughnessy.

Host: Brian P. McDonough, MD, FAAFP

Guest: Frank Diehl, PhD



A poster presented at the 2024 American Association for Cancer Research Annual Meeting showcased findings from the ASCEND 2 study, which examined the performance of a multi-cancer early detection (MCED) test design that included methylation and protein biomarkers. The study found that this test design achieved overall sensitivity of 50.9 percent for all cancers at a high specificity of 98.5 percent. Dive further into these results and what they might mean for early cancer detection with Dr. Brian McDonough and Dr. Frank Diehl, Senior Vice President of Multi Cancer Early Detection at Exact Sciences Corporation.

Host: Javier Cortes, MD, PhD

Guest: Komal Jhaveri, MD, FACP



The addition of antibody-drug conjugate (ADC) therapies to the treatment armamentarium for endocrine-refractory, HR-positive, HER2-negative metastatic breast cancer has greatly improved outcomes for patients in this setting. However, selecting the appropriate ADC and determining the optimal sequencing of these therapies may be challenging. In this activity, expert faculty in the field of breast cancer review the clinical burden related to endocrine-refractory disease, the role of ADCs in this setting, and best practices for the sequencing of these agents.

Host: Nabil F. Saba, MD, FACP

Guest: Barbara Burtness, MD



In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.

Host: Nabil F. Saba, MD, FACP

Guest: Barbara Burtness, MD



In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.

Host: Nabil F. Saba, MD, FACP

Guest: Barbara Burtness, MD



In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.